Products from BPS Bioscience require a minimum order value above 400€
Application: Great for screening small molecules and antibodies that inhibit the binding of IL-17A to IL-17R.
Background: IL-23 (interleukin 23) is a cytokine involved in inflammation. It is composed of two subunits, IL-12B (or IL-12p40) and IL-23A (or IL-23 p19) and binds to the IL-23 receptor. It supports Th17 T cell maintenance, expansion and cytokine release, NK cell IFNγ (interferon γ) secretion and increased ADCC (antibody-dependent cellular cytotoxicity) and CD4+ T cell proliferation. IL-23 is produced and secreted by activated dendritic cells, macrophages, B cells and γδ T cells. Excessive production of this cytokine can lead to autoimmune disorders, such as psoriasis, and even cancer. Ustekinumab (sold under the brand name STELARA®) and guselkumab (sold under the brand name Tremfya®) are two commercial monoclonal antibodies targeting IL-23, designed for the treatment of Crohn’s disease, ulcerative colitis, plaque and arthritic psoriasis. The success of these two drugs indicates the relevance of this cytokine in human health and disease, making it a valuable therapeutic target.
Description: The IL-23R:IL-23A[Biotynilated] Inhibitor Screening Assay Kit is designed to measure the binding of IL-23R (interleukin 23 receptor) to IL-23A (IL-23 subunit alpha) for screening and profiling applications. The IL-23R:IL-23A[Biotinylated] Inhibitor Screening Assay Kit comes in a convenient 96-well format, with enough recombinant purified biotinylated IL-23A, IL-23R, blocking and assay buffer and detection reagents for 100 enzyme reactions.
Storage Stability: One year from date of receipt when stored as directed.
Supplied As: The IL-23RA-IL-23A[Biotin] Binding Assay Kit comes in a convenient 96-well format, with biotin-labeled IL-23A, purified IL-23 Receptor alpha (IL-23RA), streptavidin-labeled HRP, and assay buffer for 100 binding reactions.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: McKenzie B.S., et al. 2006 Trends in Immunology 27(1): 17-23.Iwakura, Y. and Harumichi I. 2006 The Journal of clinical investigation 116(5): 1218-1222.Fragoulis G. and Siebert S., 2022 Musculoskeletal Care 20 (suppl 1): S12-S21.
English
Deutsch
